Elmind Capital LP Acquires Shares of 22,000 Krystal Biotech, Inc. $KRYS

Elmind Capital LP acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 22,000 shares of the company’s stock, valued at approximately $5,424,000. Krystal Biotech makes up approximately 1.6% of Elmind Capital LP’s portfolio, making the stock its 17th largest position.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in Krystal Biotech by 469.9% during the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock valued at $4,662,000 after buying an additional 15,591 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after buying an additional 39,000 shares in the last quarter. William Blair Investment Management LLC grew its holdings in Krystal Biotech by 63.9% during the 3rd quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock valued at $26,356,000 after buying an additional 58,203 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Krystal Biotech during the 3rd quarter valued at approximately $1,450,000. Finally, TD Asset Management Inc grew its holdings in Krystal Biotech by 124.5% during the 3rd quarter. TD Asset Management Inc now owns 45,080 shares of the company’s stock valued at $7,958,000 after buying an additional 25,000 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday. Wolfe Research began coverage on shares of Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating for the company. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. HC Wainwright raised their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $329.78.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

KRYS stock opened at $341.66 on Thursday. The firm has a fifty day moving average price of $292.56 and a 200 day moving average price of $270.63. Krystal Biotech, Inc. has a fifty-two week low of $127.99 and a fifty-two week high of $347.67. The firm has a market cap of $10.07 billion, a PE ratio of 45.68 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. On average, equities analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.